M&T Bank Corp Boosts Stock Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

M&T Bank Corp raised its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 7.5% during the first quarter, according to its most recent filing with the SEC. The firm owned 41,420 shares of the company’s stock after purchasing an additional 2,906 shares during the period. M&T Bank Corp’s holdings in Takeda Pharmaceutical were worth $616,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in TAK. FNY Investment Advisers LLC purchased a new position in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $37,000. Farther Finance Advisors LLC grew its position in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after buying an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. purchased a new position in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $52,000. EverSource Wealth Advisors LLC grew its position in shares of Takeda Pharmaceutical by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock worth $69,000 after buying an additional 1,770 shares during the last quarter. Finally, Fifth Third Bancorp grew its position in shares of Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after buying an additional 2,411 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Down 2.0%

NYSE:TAK opened at $14.74 on Wednesday. The company has a market cap of $46.89 billion, a PE ratio of 66.98 and a beta of 0.23. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.53. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $14.83 and its two-hundred day moving average is $14.41.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.